Protein Kinase Inhibitors: all 15,278 studies that test it

Page 101 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of ICP-192 in Solid Tumors PatientsStatus unknownNCT03758664Phase 1/2
• A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy ParticipantsCompletedNCT03758339Phase 1
• Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedNCT03758287Phase 1/2
• A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesStatus unknownNCT03757000Phase 1
• TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
• The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerStatus unknownNCT03756090Not applicable
• Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerStatus unknownNCT03756064Not applicable
• Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
• Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）Status unknownNCT03755869Phase 4
• A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedNCT03755102Early Phase 1
• Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR MutationStatus unknownNCT03754530Phase 2
• Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaStatus unknownNCT03754179Phase 1/2
• X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2
• Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial InfarctionStatus unknownNCT03753269Phase 4
• A Taste Assessment of BMS-986165 in Healthy ParticipantsCompletedNCT03751228Phase 1
• Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung CancerStatus unknownNCT03750916Phase 2
• Multiple Dose Ethnobridging PK Study in Healthy SubjectsCompletedNCT03750565Phase 1
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
• ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like SyndromeWithdrawnNCT03747328Phase 2
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
• Paclitaxel and TAK-228 in Urothelial CarcinomaStatus unknownNCT03745911Phase 2
• Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)SuspendedNCT03743428Not applicable
• Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）CompletedNCT03743129Phase 2
• A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03742882Phase 1
• Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy ParticipantsCompletedNCT03742336Phase 1
• REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
• TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCTStatus unknownNCT03741244Phase 2
• Treatment of NF1-related Plexiform Neurofibroma With TrametinibActive, not recruitingNCT03741101Phase 2
• A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
• Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingNCT03740334Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCompletedNCT03739788Phase 1
• CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCompletedNCT03739554Phase 1
• Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical TrialStatus unknownNCT03738956Phase 2/3
• Study of TG02 Citrate in Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT03738111Phase 1
• Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT03736850Phase 1
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedNCT03736837Phase 2
• Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLStatus unknownNCT03736616Phase 2
• Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisCompletedNCT03736161Phase 3
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）Status unknownNCT03735264Phase 2
• Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
• Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 DysfunctionActive, not recruitingNCT03734198Phase 2
• Anlotinib in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03732846Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid CarcinomasStatus unknownNCT03732495Phase 2
• 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompletedNCT03732352Phase 2
• Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLCCompletedNCT03732274Phase 1/2
• (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingNCT03731260Phase 2
• Ibrutinib + R-CHOP Followed by Ibrutinib MaintenanceActive, not recruitingNCT03731234Phase 2
• Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1
• A Study of WXFL10030390 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT03730142Phase 1
• Cabozantinib in Advanced Salivary Gland Cancer PatientsTerminatedNCT03729297Phase 2
• Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaStatus unknownNCT03728374Phase 2
• A Study of AZD4205 in Healthy Adult SubjectsCompletedNCT03728023Phase 1
• Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)Status unknownNCT03727763Phase 2
• Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerCompletedNCT03727724Phase 2
• Apatinib for Advanced Lung Squmamous CarcinomaStatus unknownNCT03725423Phase 4
• Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-EvobrutinibCompletedNCT03725072Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisActive, not recruitingNCT03725007Phase 1
• Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric CancerCompletedNCT03724851Phase 1/2
• The Role of Secondary Bile Acids in Intestinal InflammationTerminatedNCT03724175Phase 2/3
• Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
• A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedNCT03723395Phase 1
• A Safety Study of Tucatinib in Healthy and Hepatically-Impaired SubjectsCompletedNCT03722823Phase 1
• Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingNCT03722420Phase 3
• Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
• EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT03720873Phase 2
• Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
• A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT03718624Phase 2
• Study of TP-3654 in Patients With Advanced Solid TumorsCompletedNCT03715504Phase 1
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1
• Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLCTerminatedNCT03711422Phase 1
• Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2
• Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT03710772Phase 2
• Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid CarcinomaStatus unknownNCT03709953Phase 2
• Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerTerminatedNCT03709082Phase 1/2
• Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
• Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03707938Phase 1
• Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCLStatus unknownNCT03707847Phase 4
• Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2
• A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction CancerTerminatedNCT03707028Phase 1/2
• Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLCStatus unknownNCT03706287Phase 1/2
• International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic LeukaemiaTerminatedNCT03705507Phase 1/2
• Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy SubjectsCompletedNCT03704675Phase 1
• Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLCStatus unknownNCT03703596Phase 2
• Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
• Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder CarcinomaStatus unknownNCT03702491Phase 2
• Effect of Baricitinib Treatment on Peripheral Bone in RAStatus unknownNCT03701789Phase 3
• Ruxolitinib and Steroid As First Line Therapy for Acute GVHDTerminatedNCT03701698Phase 2
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive, not recruitingNCT03701334Phase 3
• A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLCStatus unknownNCT03700359Phase 2
• TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric CancerCompletedNCT03698825Phase 1/2
• Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRICompletedNCT03698253Not applicable
• Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesStatus unknownNCT03697668Phase 2
• MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasActive, not recruitingNCT03697512Phase 2
• Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline GliomasCompletedNCT03696355Phase 1
• Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)CompletedNCT03695510Phase 2

← Protein Kinase Inhibitors overview